- Home
- YDESW vs ERNAW Comparison
YDESW vs ERNAW Comparison
Compare YDESW & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | YDESW | ERNAW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | YDESW | ERNAW |
|---|---|---|
| Price | $0.84 | $0.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.3K | ★ 40.3K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $0.05 |
| 52 Week High | $2.85 | $0.11 |
Technical Indicators
Market Signals| Indicator | YDESW | ERNAW |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 56.67 |
| Support Level | $0.67 | $0.05 |
| Resistance Level | $1.00 | $0.11 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 67.24 | 66.72 |
Price Performance
Historical ComparisonAbout YDESW YD Bio Limited Warrants
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
About ERNAW Ernexa Therapeutics Inc. Warrants
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.